COSMO PHARM N overview

Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGM Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting 26.05.2023 / 16:30 GMT/BST Dublin, Ireland – 26 May 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders. A total of 7,512,823 ordinary shares in the share capital of Cosmo were represented at this annual general meeting of...

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings 30.03.2023 / 06:00 GMT/BST Dublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansion of the license agreement for Lumeblue™ with China Medical System Holdings Limited (“CMS”) (SEHK: 867). The expansion goes beyond the existing licensed...

Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance 23-March-2023 / 06:00 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 23 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reports full-year 2022...

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™ 22-March-2023 / 06:00 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 22 March 2023: Cosmo Pharmaceuticals N.V....

Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023 16.03.2023 / 06:00 GMT/BST Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its full-year 2022 results on Thursday, 23 March 2023 at 07:00 am CET. Cosmo invites investors, financial analysts and business/life science journalists to a live...

Cosmo Pharmaceuticals N.V. / Key word(s): Preliminary Results Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance 16-Feb-2023 / 06:00 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 16 February 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43)...

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia 21-Dec-2022 / 06:00 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyphens Pharma International...

Cosmo Pharmaceuticals N.V. / Key word(s): Study results Cosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK). In the trial, Lumeblue™ was compared to placebo in white light colonoscopy...